| Biomarker ID | 752 |
| PMID | 21917134 |
| Year | 2011 |
| Biomarker | CEP55 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Patients with Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | HR = 3.59, (95% CI: 1.50-8.60) |
| Effect on Pathways | Pathways Include:-Cytoskeletal Signaling,DNA Damage |
| Experiment | PSA Reccurence Vs No Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Specimens from 72 clinically localized PCa cases with follow-up data (29 without recurrence and 43 with recurrence) and 17 clinically localized PCa without follow-up data were collected and frozen at the time of radical prostatectomy |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | real-time PCR |
| Clinical | No |
| Remarks | Univariate Analysis |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | CEP55 |